May 8th 2024
Dolly Chang, MD, PhD, describes results from an exploratory analysis on the long-term impact of rapid fluid reduction on outcomes in DME.
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Innovations in Small Interfering RNA (siRNA) Therapy
May 8th 2024Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.
Ongoing Lp(a) Trials and Clinical Approaches to Treatment
May 8th 2024Panelists discuss ongoing clinical trials aimed at lowering Lipoprotein(a) levels, emphasizing the importance of proactive patient testing, and referring to new guidelines recommending that everyone be tested once in their lifetime.
Only 20% of Patients with Fibromyalgia Report Receiving Satisfactory Information on Pain
Pain relief and healthcare satisfaction were significantly increased in patients who were educated about their fibromyalgia and received care from a knowledgeable clinician who gave them information and guidance.